We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+14.02%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1.23B
AUM Growth
+$101M
Cap. Flow
-$21.8M
Cap. Flow %
-1.78%
Top 10 Hldgs %
30.12%
Holding
96
New
14
Increased
27
Reduced
30
Closed
13

Top Buys

Rank Stock Value
1
TDOC icon
Teladoc Health
TDOC
+$23.4M
2
ABBV icon
AbbVie
ABBV
+$21.1M
3
JNJ icon
Johnson & Johnson
JNJ
+$17M
4
MRK icon
Merck
MRK
+$14.7M
5
CVS icon
CVS Health
CVS
+$11.7M

Top Sells

Rank Stock Value
1
NVCR icon
NovoCure
NVCR
+$39.6M
2
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$25.9M
3
LVGO
Livongo Health, Inc. Common Stock
LVGO
+$23.4M
4
IMMU
Immunomedics Inc
IMMU
+$18.8M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$18.6M

Sector Composition

Rank Sector Weight
1 Healthcare 97.59%
2 Industrials 0.53%
3 Communication Services 0%
4 Consumer Discretionary 0%
5 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EPZM
76
DELISTED
Epizyme, Inc
EPZM
$2.88M 0.23%
265,000
– –
STXS icon
77
Stereotaxis
STXS
$145M
$2.87M 0.23%
+564,400
New +$2.31M
EPIX
78
DELISTED
ESSA Pharma
EPIX
$1.87M 0.15%
+156,700
New +$1.1M
AUPH icon
79
Aurinia Pharmaceuticals
AUPH
$2.04B
$1.73M 0.14%
+125,000
New +$1.82M
AMWL icon
80
American Well
AMWL
$227M
$1.52M 0.12%
+3,000
New +$1.74M
GDRX icon
81
GoodRx Holdings
GDRX
$1.31B
$1.41M 0.12%
+35,000
New +$1.61M
CTIC
82
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$966K 0.08%
+300,000
New +$998K
PVLA
83
Palvella Therapeutics
PVLA
$2.24B
$750K 0.06%
3,750
– –
ABEO icon
84
Abeona Therapeutics
ABEO
$426M
– –
-37,000
Closed -$944K
AMRN
85
Amarin Corp
AMRN
$297M
– –
-15,000
Closed -$1.26M
BLUE
86
DELISTED
bluebird bio
BLUE
– –
-8,322
Closed -$5.82M
CLLS
87
Cellectis
CLLS
$287M
– –
-144,604
Closed -$2.67M
CVX icon
88
Chevron
CVX
$385B
– –
-2,974
Closed -$214K
F icon
89
Ford
F
$55.7B
– –
-29,164
Closed -$194K
INCY icon
90
Incyte
INCY
$24.5B
– –
-40,000
Closed -$3.59M
QCOM icon
91
Qualcomm
QCOM
$171B
– –
-2,381
Closed -$280K
QURE icon
92
uniQure
QURE
$3.12B
– –
-40,466
Closed -$1.49M
RARE icon
93
Ultragenyx Pharmaceutical
RARE
$2.67B
– –
-61,500
Closed -$5.05M
MYOK
94
DELISTED
MyoKardia, Inc. Common Stock
MYOK
– –
-190,000
Closed -$25.9M
LVGO
95
DELISTED
Livongo Health, Inc. Common Stock
LVGO
– –
-166,961
Closed -$23.4M
IMMU
96
DELISTED
Immunomedics Inc
IMMU
– –
-221,351
Closed -$18.8M
1 2 3
4

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2020 Portfolio in Review

As of Q4 2020, Rhenman & Partners Asset Management held 96 positions worth $1.23B, up 9% from $1.12B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Rhenman & Partners Asset Management's Q4 2020 filing shows 14 new, 27 increased, 30 reduced and 13 closed positions. Its largest new stake was Teladoc Health: 115,000 shares worth $23M. The largest sale was NovoCure, an estimated $39.6M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 94% a quarter earlier, followed by Industrials and Communication Services.

  • Rhenman & Partners Asset Management's largest Q4 2020 buy was Teladoc Health: 115,000 shares worth $23M.
  • Rhenman & Partners Asset Management added most to AbbVie in Q4 2020, an estimated $21.1M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2020 reduction was NovoCure, cutting an estimated $39.6M.
  • Rhenman & Partners Asset Management fully exited MyoKardia, Inc. Common Stock in Q4 2020, selling an estimated $25.9M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 30% of its $1.23B portfolio in Q4 2020.
  • Rhenman & Partners Asset Management opened 14 new positions and closed 13 in Q4 2020.
  • Rhenman & Partners Asset Management's portfolio value rose 9% quarter-over-quarter to $1.23B.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2020, filed 19 Jan 2021.